 |
|
 |
 |

Home > Company Index > Drugs > Biotechnology-Medicine > Titan Pharmaceuticals, Inc.
 |
Titan Pharmaceuticals, Inc. |
 |
 |
 |
NEWS FROM THE STANDARD |
 |
The Trouble With the Miracle Business
Jul 25 2001 06:25 AM PDT
PROFILE |
 |
Titan Pharmaceuticals thinks big. The development-stage firm identifies and acquires new drug technology, often from universities, to avoid the costs of early-stage drug development. Zomaril, its flagship drug candidate being developed with Novartis, targets schizophrenia. With Schering AG, the company is testing Spheramine to fight Parkinson's disease. Also in the pipeline are treatments for breast, colon, lung, skin, and other cancers. Subsidiary ProNeura is working on an implantable drug delivery system to combat central nervous system disorders, while another unit, Ingenex, is developing gene therapy cancer treatments.
COMPETITION |
 |
Amgen Inc. (AMGN)
Eli Lilly and Company (LLY)
Progenics Pharmaceuticals, Inc. (PGNX)
|
 |
STOCK ANALYSIS |
 |
FURTHER ANALYSIS
Advanced Charting
Deals
FINANCIAL OVERVIEW |
 |
Fiscal Year-End: December
2000 Sales (mil.): 1.90
1-Yr. Sales Growth: 533.3%
Employees: 46
Revenue per employee: $41,304.35
KEY PEOPLE |
 |
Louis R. Bucalo
CEO
Robert E. Farrell
CFO
CONTACT INFO |
 |
400 Oyster Point Blvd., Ste. 505
South San Francisco, CA 94080
US
Phone: 650-244-4990
Fax: 650-244-4956
Online: Web Site
|
 |
 |
 |
|
Hoover's Company Capsule
Copyright © 2001, Hoover's Inc. Austin, Texas.
For changes and updates, contact Hoover's directly.
|

|
 |
 |
|
 |